Ramamoorthy Nagasubramanian, MD
Hematology/Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Looking this up.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nagasubramanian’s office at (650) 498-7200 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence C192061 · Current
Licensed to practise in California · since 2023 · expires 2027-11-30 · University of Madras, Kilpauk Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Illinois 036091120Licensed Physician And Surgeon · since 1995 · expires 2008-07-31Not RenewedNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Medicaid work
$18,078 in 2024
Medicaid paid $18,078 for 207 billed services this clinician did in 2024, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 66 | $6,079 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 62 | $5,273 |
| COMPREHENSIVE METABOLIC PANEL | 28 | $2,457 |
| Short return visit (20+ min) | 15 | $1,188 |
| Blood group typing (ABO) | 12 | $1,038 |
| Antihuman globulin test (Coombs test); indirect, qualitative, each reagent red cell | 12 | $1,021 |
| Blood typing for Rh (D) antigen | 12 | $1,021 |
| 2024 | 207 | 7 | 21 | $18,078 |
| 2023 | 1,537 | 14 | 47 | $116,831 |
| 2022 | 1,192 | 8 | 61 | $112,210 |
| 2021 | 957 | 5 | 52 | $83,127 |
| 2020 | 688 | 8 | 29 | $83,306 |
| 2019 | 1,052 | 7 | 50 | $154,562 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 442 | $36,185 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 260 | $15,036 |
| COMPREHENSIVE METABOLIC PANEL | 240 | $14,102 |
| Short return visit (20+ min) | 171 | $13,287 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 53 | $8,365 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 36 | $6,556 |
| 1ST HOSP IP/OBS HIGH 75 | 14 | $5,393 |
| Blood group typing (ABO) | 69 | $4,192 |
| Antihuman globulin test (Coombs test); indirect, qualitative, each reagent red cell | 69 | $4,129 |
| Blood typing for Rh (D) antigen | 69 | $4,129 |
| Compatibility test each unit; electronic | 17 | $2,924 |
| BLOOD COUNT RETICULOCYTE AUTOMATED | 19 | $1,361 |
2022
| Long return visit (40+ min) | 433 | $42,575 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 237 | $27,490 |
| Short return visit (20+ min) | 369 | $26,342 |
| Return visit (30+ min) | 67 | $6,439 |
| 1ST HOSP IP/OBS HIGH 75 | 14 | $4,594 |
| Short return visit | 39 | $2,188 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 13 | $2,106 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 20 | $475 |
2021
| Long return visit (40+ min) | 636 | $60,501 |
| Short return visit (20+ min) | 248 | $15,356 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 43 | $5,382 |
| Return visit (30+ min) | 17 | $1,839 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 13 | $49 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 172 | $23,034 |
| Long return visit (40+ min) | 142 | $22,912 |
| Return visit (30+ min) | 209 | $22,616 |
| Short return visit (20+ min) | 95 | $7,595 |
| 1ST HOSP IP/OBS HIGH 75 | 17 | $6,931 |
| COMPREHENSIVE METABOLIC PANEL | 17 | $114 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 18 | $105 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 18 | $0 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 298 | $43,246 |
| Return visit (30+ min) | 312 | $35,429 |
| Long return visit (40+ min) | 212 | $30,781 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 95 | $26,324 |
| 1ST HOSP IP/OBS HIGH 75 | 31 | $9,785 |
| Short return visit (20+ min) | 89 | $7,538 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 15 | $1,458 |
Money from drug and device companies
$28 in 2025
| 2025 | 1 | 1 | None | $28 |
| 2023 | 1 | 1 | None | $83 |
| 2020 | 2 | 2 | $2,560 | $2,581 |
| 2019 | 1 | 11 | $12,580 | $13,223 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Vijoice | $28 | 1 payment
|
See the published payment
| Novartis Pharmaceuticals | Meals · 2025-02-05 | Vijoice | $28 |
See earlier years (2023, 2020, 2019)
2023: $83
| Fennec Pharmaceuticals | Pedmark | $83 | 1 payment
|
2020: $2,581
| Bayer HealthCare Pharmaceuticals | Vitrakvi | $2,560 | 1 payment
|
| Global Blood Therapeutics | Oxbryta | $21 | 1 payment
|
2019: $13,223
| Bayer HealthCare Pharmaceuticals | Vitrakvi | $13,223 | 11 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| JAZZ PHARMACEUTICALS INC. · A Phase 3 Randomized Trial for Patients With De Novo Aml Comparing Standard Therapy Including Gemtuzumab Ozogamicin Go To Cpx351 With Go · 2022 | Their institution | $270,750 |
| JAZZ PHARMACEUTICALS INC. · A Study To Compare Standard Chemotherapy To Therapy With Cpx-351 and/Or Gilteritinib for Patients With Newly Diagnosed Aml With Or Without Flt3 Mutations · 2020 | Their institution | $177,841 |
| E.R. Squibb & Sons, L.L.C. · 9400530000 Bms Accl1333 - Cog - Bms- Accl1333 / Apixaban · 2022 | Their institution | $141,265 |
| ABBVIE INC. · B19-061 Ph 3 Pediatric Study of Venetoclax and Chemotherapy · 2024 | Their institution | $63,300 |
| E.R. Squibb & Sons, L.L.C. · Phase III Vte Prev With Children With All · 2020 | Their institution | $41,729 |
| Novartis Pharmaceuticals Corporation · A Multi Center Open Label Non Controlled Phase II Study To Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph Chronic Myelogenous Leukemia Cml in Chronic Phase Cp Or With Ph Cml in Cp Or Accelerated Phase Ap Resis · 2019 | Their institution | $32,448 |
| Novo Nordisk AS · 2019 | Their institution | $17,769 |
| Eli Lilly and Company · A Phase 1/2 Study of the Oral Ret Inhibitor Loxo 292 in Pediatric Patients With Advanced Ret-Altered Solid Or Primary Central Nervous System Tumors · 2022 | Their institution | $9,300 |
| Helsinn Healthcare SA · A Multicenter, Multinational, Randomized, Double-Blind, Pharmacokinetic and Pharmacodynamic (Pk/Pd) Dose-Finding Study of Oral Netupitant Administered Concomitantly With Oral Palonosetron in Pediatric Cancer Patients for the Prevention of Nausea and Vomiting Associated With Emetogenic Chemotherapy. · 2020 | Their institution | $7,880 |
| PFIZER INC. · A Phase 12 Study To Evaluate the Safety and Pharmacokinetics of Bosutinib in Pediatric Patients With Cml Who Are Resistant Or Intolerant To at Least One Prior Tyrosine Kinase Inhibitor Therapy · 2022 | Their institution | $7,500 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2024 | Their institution | $7,000 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2023 | Their institution | $7,000 |
| Helsinn Healthcare SA · A Multicenter, Multinational, Randomized, Double-Blind, Pharmacokinetic and Pharmacodynamic Pkpd Dose-Finding Study of Oral Netupitant Administered Concomitantly With Oral Palonosetron in Pediatric Cancer Patients for the Prevention of Nausea and Vomiting Associated With Emetogenic Chemotherapy. · 2019 | Their institution | $5,315 |
| Novartis Pharmaceuticals Corporation · A Multi Center Open Label Non Controlled Phase II Study To Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph Chronic Myelogenous Leukemia Cml in Chronic Phase Cp Or With Ph Cml in Cp Or Accelerated Phase Ap Resis · 2020 | Their institution | $2,800 |
| Eli Lilly and Company · A Phase 1/2 Study of the Oral Ret Inhibitor Loxo 292 in Pediatric Patients With Advanced Ret-Altered Solid Or Primary Central Nervous System Tumors · 2025 | Their institution | $2,750 |
| Novartis Pharmaceuticals Corporation · A Multi Center Open Label Non Controlled Phase II Study To Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph Chronic Myelogenous Leukemia Cml in Chronic Phase Cp Or With Ph Cml in Cp Or Accelerated Phase Ap Resistant Or Intolerant To Either Imatinib Or Dasatinib · 2021 | Their institution | $2,000 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2021 | Their institution | $1,000 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2019 | Their institution | $1,000 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2022 | Their institution | $747 |
Professional record
- NPI
- 1134279177
- Licence
- CA C192061, IL 036091120California C192061: Current · expires 2027-11-30Illinois 036091120: Not Renewed
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- IL 036091120
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2007-01-11
- NPI last updated
- 2024-05-14
- NPI record certified
- 2024-05-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1717 S Orange Ave, Orlando, FL, 32806 · Po Box 191, Rockland, DE, 19732